NCT01930058View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 2, 2013

Primary Completion Date

May 5, 2014

Study Completion Date

May 5, 2014

Conditions
Hepatitis C
Interventions
DRUG

MK-8876

MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01930058 - Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) | Biotech Hunter | Biotech Hunter